Literature DB >> 29746291

Personalized Dosing Versus Fixed Dosing of Immune Checkpoint Inhibitors: A Cost Analysis Study.

Sarbajit Mukherjee1, Sami Ibrahimi1, Michael Machiorlatti2, Darwin Roman3, Rabia Saleem3, Ayesha Hassan3, Allison Baxley4, Sara Vesely5, Raid Aljumaily1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29746291     DOI： 10.1097/MJT.0000000000000774

Source DB:  PubMed          Journal:  Am J Ther        ISSN： 1075-2765            Impact factor:   2.688


× No keyword cloud information.
  6 in total

Review 1.  Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response.

Authors:  Vishal Navani; Moira C Graves; Nikola A Bowden; Andre Van Der Westhuizen
Journal:  Br J Clin Pharmacol       Date:  2020-06-05       Impact factor: 4.335

2.  Sequencing Systemic Therapy Pathways for Advanced Hepatocellular Carcinoma: A Cost Effectiveness Analysis.

Authors:  Christopher Sherrow; Kristopher Attwood; Kehua Zhou; Sarbajit Mukherjee; Renuka Iyer; Christos Fountzilas
Journal:  Liver Cancer       Date:  2020-08-12       Impact factor: 11.740

3.  Is flat dosing cost-effective? Re: 'The same old story': thoughts on authorised doses of anticancer drugs.

Authors:  Abdul R Farooq; Timothy O'Brien; Seamus O'Reilly
Journal:  Ther Adv Med Oncol       Date:  2020-12-25       Impact factor: 8.168

Review 4.  Immunotherapy and Radiotherapy for Older Cancer Patients during the COVID-19 Era: Proposed Paradigm by the International Geriatric Radiotherapy Group.

Authors:  Nam Phong Nguyen; Brigitta G Baumert; Eromosele Oboite; Micaela Motta; Gokula Kumar Appalanaido; Meritxell Arenas; Pedro Carlos Lara; Marta Bonet; Alice Zamagni; Te Vuong; Tiberiu Popescu; Ulf Karlsson; Lurdes Trigo; Arthur Sun Myint; Juliette Thariat; Vincent Vinh-Hung
Journal:  Gerontology       Date:  2021-03-30       Impact factor: 5.140

Review 5.  Is immunotherapy at reduced dose and radiotherapy for older patients with locally advanced non-small lung cancer feasible?-a narrative review by the international geriatric radiotherapy group.

Authors:  Vincent Vinh-Hung; Olena Gorobets; Andre Duerinkcx; Suresh Dutta; Eromosele Oboite; Joan Oboite; Ahmed Ali; Thandeka Mazibuko; Ulf Karlsson; Alexander Chi; David Lehrman; Omer Hashim Mohammed; Mohammad Mohammadianpanah; Gokoulakrichenane Loganadane; Natalia Migliore; Maria Vasileiou; Nam P Nguyen; Huan Giap
Journal:  Transl Cancer Res       Date:  2022-09       Impact factor: 0.496

6.  Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors.

Authors:  Murtaza Ahmed; Mitchell S von Itzstein; Thomas Sheffield; Shaheen Khan; Farjana Fattah; Jason Y Park; Vinita Popat; Jessica M Saltarski; Yvonne Gloria-McCutchen; David Hsiehchen; Jared Ostmeyer; Saad A Khan; Nazima Sultana; Yang Xie; Quan-Zhen Li; Edward K Wakeland; David E Gerber
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.